Skip to main content
Article
Apolipoprotein A-I mimetic peptide L-4F prevents myocardial and coronary dysfunction in diabetic mice
Biochemistry and Microbiology
  • C. Vecoli
  • J. Cao
  • D. Neglia
  • K. Inoue
  • Komal Sodhi, Marshall University
  • L. Vanella
  • K. K. Gabrielson
  • D. Bedja
  • N. Paolocci
  • A. L'Abbate
  • Nader G. Abraham, Marshall University
Document Type
Article
Publication Date
9-1-2012
Abstract
Diabetes is a major health problem associated with adverse cardiovascular outcomes. The apolipoprotein A-I mimetic peptide L-4F is a putative anti-diabetic drug, has antioxidant and anti-inflammatory proprieties and improves endothelial function. In obese mice L-4F increases adiponectin levels, improving insulin sensitivity and reducing visceral adiposity. We hypothesized that the pleiotropic actions of L-4F can prevent heart and coronary dysfunction in a mouse model of genetically induced Type II diabetes. We treated db/db mice with either L-4F or vehicle for 8 weeks. Trans-thoracic echocardiography was performed; thereafter, isolated hearts were subjected to ischemia/reperfusion (IR). Glucose, insulin, adiponectin, and pro-inflammatory cytokines (IL-1β, TNF-α, MCP-1) were measured in plasma and HO-1, pAMPK, peNOS, iNOS, adiponectin and superoxide in cardiac tissue. In db/db mice L-4F decreased accumulation of subcutaneous and total fat, and increased insulin sensitivity and adiponectin levels while lowering inflammatory cytokines (p<0.05). L-4F normalized in vivo left ventricular (LV) function of db/db mice, increasing (p<0.05) fractional shortening and decreasing (p<0.05) LV dimensions. In I/R experiments, L-4F prevented coronary microvascular resistance from increasing and LV function from deteriorating in the db/db mice. These changes were associated with increased cardiac expression of HO-1, pAMPK, peNOS and adiponectin and decreased levels of superoxide and iNOS (p<0.01). In the present study we showed that L-4F prevented myocardial and coronary functional abnormalities in db/db mice. These effects were associated with stimulation of HO-1 resulting in increased levels of anti-inflammatory, anti-oxidative, and vasodilatatory action through a mechanism involving increased levels of adiponectin, pAMPK and peNOS.
Comments

The version of record is available from the publisher at http://dx.doi.org/10.1002%2Fjcb.23188. Copyright © 2011 Wiley-Liss, Inc. All rights reserved.

Citation Information
Vecoli C, Cao J, Neglia D, Inoue K, Sodhi K, Vanella L, Gabrielson KK, Bedja D, Paolocci N, L'abbate A, Abraham NG. Apolipoprotein A‐I mimetic peptide L‐4F prevents myocardial and coronary dysfunction in diabetic mice. Journal of cellular biochemistry. 2011 Sep 1;112(9):2616-26.